ArriVent BioPharma, Inc.
AVBP
$25.22
$0.331.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -127.46M | -80.49M | -81.05M | -74.89M | -74.58M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.85M | 3.21M | 2.58M | 1.93M | 1.35M |
| Change in Net Operating Assets | 3.01M | 7.07M | 9.50M | 4.89M | 15.64M |
| Cash from Operations | -119.59M | -70.21M | -68.97M | -68.07M | -57.59M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -155.64M | -192.47M | 25.00M | 25.00M | 0.00 |
| Cash from Investing | -155.64M | -192.47M | 25.00M | 25.00M | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.76M | 186.58M | 186.81M | 186.32M | 185.96M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -24.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -50.00K | -- | -1.34M | -2.41M | -2.41M |
| Cash from Financing | 7.71M | 186.58M | 185.47M | 183.91M | 183.52M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -267.53M | -76.10M | 141.50M | 140.84M | 125.93M |